سعر سافيبليد 500مجم/5مل 5 امبولات 2024

Savibleed injection (Marcyrl, Egypt): tranexamic acid 500 mg/5 ml solution in ampoules, pack of 5 ampoules; antifibrinolytic.

• Prevention and treatment of haemorrhage due to general or local fibrinolysis in adults and children from one year (e.g. menorrhagia and metrorrhagia, gastrointestinal bleeding, haemorrhagic urinary disorders after prostate/urinary tract surgery, ENT surgery including dental extraction, gynaecological/obstetric bleeding, thoracic, abdominal and cardiovascular surgery)electronic medicines compendium (emc), UK
• Management of haemorrhage due to the administration of a fibrinolytic agentelectronic medicines compendium (emc), UK

• Common: diarrhoea, vomiting, nausea. Uncommon: allergic dermatitis. Frequency not known: hypersensitivity including anaphylaxis, convulsions (particularly with misuse), visual disturbances including impaired colour vision, malaise with hypotension (generally after too fast IV injection), arterial or venous thrombosis.International label, same formulation · electronic medicines compendium (emc), UK

• Hypersensitivity; acute venous or arterial thrombosis; fibrinolytic conditions following consumption coagulopathy (except predominant fibrinolytic activation with acute severe bleeding); history of convulsions; intrathecal, epidural, intraventricular injection and intracerebral application.International label, same formulation · electronic medicines compendium (emc), UK
• US label: contraindicated as a neuraxial (intrathecal, epidural) injection; in subarachnoid haemorrhage (risk of cerebral oedema and infarction); in active intravascular clotting; hypersensitivity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Risk of fatal medication errors if given by the wrong route; inject very slowly; not intramuscular.International label, same formulation · electronic medicines compendium (emc), UK
• Convulsions reported, mostly with high IV doses in cardiac (CABG) surgery; visual disturbances may require discontinuation and regular eye examinations with long-term use.International label, same formulation · electronic medicines compendium (emc), UK
• Upper urinary tract haematuria: risk of urinary obstruction. Consider thromboembolic risk factors; use with care with hormonal contraception; generally not for DIC.International label, same formulation · electronic medicines compendium (emc), UK

• AnticoagulantsSimultaneous treatment must take place under strict supervision of an experienced physician.electronic medicines compendium (emc), UK
• Hormonal contraceptionIncreased thrombus-formation potential.electronic medicines compendium (emc), UK
• Thrombolytic drugsMay antagonise the antifibrinolytic action of tranexamic acid.electronic medicines compendium (emc), UK

• Published data in the second and third trimester and at delivery have not clarified a drug-associated risk; foetal structural abnormalities were reported after first-trimester exposure with confounders; animal studies show no harmful effects; crosses the placenta (cord blood about equal to maternal). Use requires an accurate risk-benefit evaluation.International label, same formulation · electronic medicines compendium (emc), UK
• Present in human milk; limited data; no final assessment can be established on use during breast-feeding.International label, same formulation · electronic medicines compendium (emc), UK

• Tranexamic acid: Blocks the lysine-binding sites of plasminogen, inhibiting plasminogen activation and plasmin-mediated fibrinolysis.